Table 3 Safety of AZL-M and ACE-inhibitors during 12 month follow-up
AZL-M | ACE-inhibitor | p-value | |||
|---|---|---|---|---|---|
(n = 2 237) | (n = 845) | ||||
mean ± SD or % | mean ± SD or % | ||||
Patients without an AE, % | 92.9 | 93.3 | 0.73 | ||
Patients with an AE, % | 7.1 | 6.7 | 0.73 | ||
Laboratory values | Baseline AZL-M | ∆ at 12 months FU | Baseline ACEi | ∆ at 12 months FU | p-value ∆ AZL-M vs. ∆ ACEi |
HbA1c, % | 5.9 ± 1.2 | 0.01 ± 0.97 | 5.9 ± 1.3 | 0.08 ± 0.95 | 0.94 |
Fasting glucose, mg/dl | 100.0 ± 27.0 | 3.00 ± 57.35 | 101.3 ± 24.8 | 1.39 ± 18.35 | 0.56 |
Creatinine, mg/dl | 1.2 ± 0.8 | −0.02 ± 0.82 | 1.3 ± 1.0 | −0.05 ± 0.82 | 0.17 |
Potassium, mmol/l | 4.1 ± 0.5 | 0.02 ± 0.47 | 4.1 ± 0.5 | 0.03 ± 0.50 | 0.70 |
eGFR, ml/min/1.73 m2 | 62.3 ± 18.7 | −1.79 ± 12.61 | 64.0 ± 20.5 | −0.24 ± 13.15 | 0.23 |